VRCA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 109800 min ago

@ $5.55

Išleistas: 13 vas. 2024 @ 17:00

Grąža: 28.94%

Ankstesnis signalas: vas. 9 - 18:12

Ankstesnis signalas: Pardavimas

Grąža: 2.31 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States...

Stats
Šios dienos apimtis	342 411
Vidutinė apimtis	137 296
Rinkos kapitalizacija	303.30M
EPS	$0 ( 2024-02-29 )
Kita pelno data	( $-0.530 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.83
ATR14	$0.0230 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Hayes Christopher G.	Buy	40 000	Common Stock
2024-03-15	Hayes Christopher G.	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Goldenberg Gary	Buy	40 000	Common Stock
2024-03-15	Goldenberg Gary	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Kohler Terry	Buy	80 000	Employee Stock Option (right to buy)

INSIDER POWER
90.98
Last 98 transactions
Buy: 14 420 498 \| Sell: 288 608

Tūris Koreliacija

Ilgas: -0.05 (neutral)

Trumpas: -0.77 (moderate negative)

Signal:(71.027) Neutral

Verrica Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TGTX	0.959
IDCC	0.956
SLMBP	0.955
VBOCU	0.955
RAM	0.95
WKEY	0.95
OVLY	0.948
NCAC	0.947
MESA	0.946
GPACU	0.945

10 Labiausiai neigiamai susiję koreliacijos
CBNK	-0.945
CYTO	-0.939
GSMG	-0.938
GNTY	-0.936
BFRI	-0.936
FGBI	-0.936
GOOD	-0.934
AMNB	-0.93
CMLS	-0.929
ALHC	-0.927

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Verrica Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.28
( neutral )

0.30
( neutral )

0.00
( neutral )

0.27
( neutral )

-0.42
( neutral )

-0.30
( neutral )

Verrica Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$5.12M
Bruto pelnas:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2023
Pajamos:	$5.12M
Bruto pelnas:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2022
Pajamos:	$9.03M
Bruto pelnas:	$8.31M (91.97 %)
EPS:	$-0.810

FY	2021
Pajamos:	$12.00M
Bruto pelnas:	$12.00M (100.00 %)
EPS:	$-1.300

Financial Reports:

No articles found.

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.